QIAGEN N.V. Operating Income Loss

• QIAGEN N.V. showed an increase of +376.8% in Operating Income Loss from 2024 to 2025.
• This data is from QIAGEN N.V.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
• XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 18 years of available data (2008 to 2025), QIAGEN N.V.'s Operating Income Loss has grown by 219.8%.
• Historical annual values: Fiscal year 2025: $465.85 million | Fiscal year 2024: $97.71 million | Fiscal year 2023: $409.94 million | Fiscal year 2022: $531.46 million | Fiscal year 2021: $630.08 million | Fiscal year 2020: $386.43 million | Fiscal year 2019: -$26.14 million | Fiscal year 2018: $266.58 million | Fiscal year 2017: $153.42 million | Fiscal year 2016: $98.83 million | Fiscal year 2015: $179.50 million | Fiscal year 2014: $161.69 million | Fiscal year 2013: $63.33 million | Fiscal year 2012: $169.81 million | Fiscal year 2011: $99.59 million | Fiscal year 2010: $188.54 million | Fiscal year 2009: $180.21 million | Fiscal year 2008: $145.66 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026